CheryTree, I was referring to the small set of patients in the paper Avii referenced yesterday. I noted that the link he’d given was to a paper with a pay wall, and so the only criteria we could see was that some of them were methylated, some were unmethylated (specific percentages were unknown), and that all the patients had GBM. We can’t compare sex, age, K-scores, or any other criteria to the DCVax trial population.
Market Data 
Markets 
AI
